XRAY icon

Dentsply Sirona

13.62 USD
0.00
0%
At close Updated Sep 17, 11:58 AM EDT
1 day
0%
5 days
-0.22%
1 month
-1.73%
3 months
-11.39%
6 months
-12.64%
Year to date
-27.36%
1 year
-48.97%
5 years
-71.46%
10 years
-74.57%
 

About: Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).

Employees: 14,000

0
Funds holding %
of 7,463 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

146% more call options, than puts

Call options by funds: $5.42M | Put options by funds: $2.2M

83% more repeat investments, than reductions

Existing positions increased: 168 | Existing positions reduced: 92

71% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 49

25% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]

9% more funds holding

Funds holding: 355 [Q1] → 386 (+31) [Q2]

7% more capital invested

Capital invested by funds: $2.96B [Q1] → $3.17B (+$210M) [Q2]

0.55% more ownership

Funds ownership: 99.47% [Q1] → 100.02% (+0.55%) [Q2]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$15
10% upside
Avg. target
$18.5
36% upside
High target
$24
76% upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
UBS
Kevin Caliendo
$24
Buy
Maintained
8 Aug 2025
Barrington Research
Michael Petusky
$18
Outperform
Maintained
8 Aug 2025
Wells Fargo
Vik Chopra
$15
Equal-Weight
Maintained
8 Aug 2025
Stifel
Jonathan Block
$17
Hold
Maintained
8 Aug 2025

Financial journalist opinion

Based on 9 articles about XRAY published over the past 30 days

Neutral
Zacks Investment Research
7 days ago
Dentsply Sirona Retains Wellspect Following Strategic Review
XRAY will keep its Wellspect unit, betting on its strong cash flows and $2B market to deliver greater long-term shareholder value.
Dentsply Sirona Retains Wellspect Following Strategic Review
Neutral
Seeking Alpha
7 days ago
DENTSPLY SIRONA Inc. (XRAY) Presents At Baird 2025 Global Healthcare Conference (Transcript)
DENTSPLY SIRONA Inc. (NASDAQ:XRAY ) Baird 2025 Global Healthcare Conference September 9, 2025 1:25 PM EDT Company Participants Matthew Garth - Executive VP & CFO Conference Call Participants Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Presentation Jeffrey Johnson Senior Research Analyst All right.
DENTSPLY SIRONA Inc. (XRAY) Presents At Baird 2025 Global Healthcare Conference (Transcript)
Neutral
Seeking Alpha
8 days ago
DENTSPLY SIRONA Inc. (XRAY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
DENTSPLY SIRONA Inc. (NASDAQ:XRAY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Daniel Scavilla - President, CEO & Director Matthew Garth - Executive VP & CFO Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Good afternoon, everyone. My name is Erin Wright, the health care services analyst at Morgan Stanley.
DENTSPLY SIRONA Inc. (XRAY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral
GlobeNewsWire
9 days ago
Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives
Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the Company Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the Company
Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives
Positive
Benzinga
12 days ago
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields
Neutral
GlobeNewsWire
21 days ago
Dentsply Sirona to Participate in Upcoming Investor Conferences
CHARLOTTE, N.C., Aug. 26, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its participation at upcoming conferences.
Dentsply Sirona to Participate in Upcoming Investor Conferences
Neutral
Zacks Investment Research
27 days ago
Is the Options Market Predicting a Spike in DENTSPLY Stock?
Investors need to pay close attention to XRAY stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in DENTSPLY Stock?
Positive
Benzinga
28 days ago
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Positive
Seeking Alpha
29 days ago
Dentsply Sirona: Turnaround Potential And Digital Workflows
XRAY's EDS and Wellspect are the key to stabilizing their results going forward. OIS and CTS continue to decline, but SureSmile grows in Europe. Their new CEO will also prioritize execution, rather than reinventing XRAY. They'll double down on integrated digital workflows and better customer experience. If they build a stickier ecosystem, I think XRAY does have the potential for a turnaround.
Dentsply Sirona: Turnaround Potential And Digital Workflows
Neutral
Zacks Investment Research
1 month ago
International Markets and Dentsply (XRAY): A Deep Dive for Investors
Explore Dentsply's (XRAY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
International Markets and Dentsply (XRAY): A Deep Dive for Investors
Charts implemented using Lightweight Charts™